What indicators need to be monitored during treatment with valganciclovir/vansevir?

The efficacy and safety of Valganciclovir are highly dependent on monitoring and management, especially for patients in an immunosuppressed state. During medication, doctors usually develop a follow-up plan based on individual patient differences, the most critical of which is the monitoring of hematology and renal function indicators. These two aspects directly determine whether the drug can be used safely and continuously.

The first thing that needs to be focused on is the routine blood indicators. A common adverse effect of valganciclovir is bone marrow suppression, so levels of white blood cells, hemoglobin, and platelets must be tested regularly. In the event of severe neutropenia or thrombocytopenia, dose suspension or adjustment may be necessary. This kind of monitoring can not only detect drug side effects in time, but also help doctors determine whether the patient's immune status is sufficient to resist infection.

The second step is renal function monitoring. Since valganciclovir is mainly excreted by the kidneys, serum creatinine and estimated glomerular filtration rate (eGFR) are core indicators. For patients with renal insufficiency, drug dosage needs to be adjusted individually in accordance with the recommendations of the US FDA and European guidelines. Without monitoring, the drug may accumulate in the body, leading to a significantly increased risk of toxicity.

In addition to hematology and renal function, some high-risk patients will also monitor liver function and electrolyte status, which is especially important when combined with other drug treatments. Drug-drug interactions may increase the burden on the liver and kidneys, so comprehensive evaluation can help avoid multiple adverse reactions. For patients who have received organ transplants, regular CMV DNA quantitative testing may also be performed to determine the viral replication status to guide whether to continue to maintain medication or adjust the course of treatment.

In clinical practice, it is common practice for patients to monitor blood routine and renal function once a week in the early stages of medication, and after stabilization, it can be gradually extended to once a month. However, for people with risk factors, such as advanced age and those taking immunosuppressants or chemotherapy drugs, monitoring frequency is usually higher.

Reference materials:https://go.drugbank.com/drugs/DB01610